Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + Cisplatin
Phase 2RecruitingDevelopment Stage
Endometrial Cancer
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Sep 6, 2022 → Oct 1, 2027
About Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + Cisplatin
Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + Cisplatin is a phase 2 stage product being developed by Daiichi Sankyo for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05489211. Target conditions include Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05489211 | Phase 2 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer